August 25th 2025
Regulators cite four new serious adverse event reports, halting US distribution while global access efforts continue.
Valneva, Pfizer Report Further Positive Data for Investigational Lyme Disease Vaccine
February 4th 2022A sub-analysis of phase 2 data compared the immunogenicity of their VLA15 vaccine in adults after administration of 2 or 3 primary series doses with the latter demonstrating a stronger response.
Read More